Landsteiner has restructured its debt and received an equity injection from BID Group
Landsteiner Scientific has completed the successful restructuring of US$190 million of debt under Chapter 11 and has received an equity injection of US$ 20 million from BID Group.
Founded in 1998, Landsteiner is a Mexican pharmaceutical company leader on the development, manufacture and distribution of generic and biotechnological healthcare products. The company operates two state-of-the-art pharmaceutical plants. Landsteiner has over 100 registered molecules from 16 different therapeutic areas and has over 200 different product presentations.
BID Group is an investment fund founded in Mexico City. The group consists of seven business units successfully built over the past 25 years: payroll loan, financial services, IT projects, energy/power supply, construction and operation of infrastructures, venture capital and medical supply solutions.
Oaklins’ team in Mexico acted as the financial advisor to Landsteiner Scientific in the debt restructuring as well as in the structuring of the stock acquisition by BID Group.
Talk to the deal team
Related deals
Lumiforte partners with Kartesia to propel global growth and innovation
Lumiforte, a global leader in innovative smart coatings for greenhouse horticulture, sports line-marking and other functional coatings for agriculture and industry, is excited to announce an investment from Kartesia, a European specialist in capital solutions for small and medium-sized companies. Horticoop, a longstanding shareholder of Lumiforte and a key player in the horticultural industry through its investment cooperative, continues to remain a shareholder.
Learn moreYxion has been acquired by Normec
Normec has acquired Dutch consultancy Yxion from Antea. Through this acquisition, Normec continues its acquisition strategy in Europe, while also looking for expansion opportunities in the United States.
Learn moreAMC Media Group has been acquired by Formedics
AMC Media Group, a healthcare professional (HCP) community platform that enables medical associations and key opinion leaders (KOLs) to drive engagement and monetization through their specialty digital properties, has been acquired by Formedics, an HCP community and engagement platform that is home to Physician’s Weekly and OncWeekly.
Learn more